Mission & Purpose

01 / Our positioning

HopeAI — The AI Partner of Choice for Drug Development

Bringing a new medicine to patients requires the coordinated efforts of scientists, clinicians, statisticians, regulatory experts, and commercial teams, often spanning many years and hundreds of millions of dollars.

HopeAI is building an AI-native workspace for drug development, bringing together specialized AI agents, proprietary data, and validated workflows to help biopharmaceutical companies develop medicines faster, more efficiently, and with greater confidence.

Our customers range from emerging biotechnology companies to global pharmaceutical enterprises. They engage HopeAI not simply to automate individual tasks, but to address some of their most important scientific and development challenges.

We aim to become their long-term AI Partner, combining specialized intelligence with deep domain expertise to deliver measurable outcomes throughout the drug development lifecycle.

Our ambition extends beyond improving existing workflows. We envision a future in which AI-native drug development becomes the standard operating model for the life sciences industry.

02 / The platform

HopeAI Workspace — An Integrated Platform for Specialized Intelligence

We believe transforming drug development requires more than increasingly capable general-purpose AI models.

Drug development operates within complex scientific, clinical, regulatory, and organizational environments. Successful AI deployment requires specialized domain knowledge, reliable evidence, access to proprietary data, validated analytical methods, and integration with existing workflows.

HopeAI Workspace is designed to bring these capabilities together into a unified environment.

These capabilities are designed to be composable and interoperable. Agents can access shared data, invoke specialized tools, collaborate with other agents, and execute increasingly complex workflows.

Our goal is to enable customers to move seamlessly from individual tasks to coordinated, end-to-end drug development activities.

As the capabilities of our underlying AI models improve, we expect the specialized intelligence available through HopeAI Workspace to become increasingly powerful.

03 / Applications

Applications Built on HopeAI Workspace

HopeAI develops specialized applications that make advanced AI capabilities accessible to drug development professionals. Our applications address critical activities across the development lifecycle.

TrialScape

Democratizes access to clinical trial intelligence, enabling users to discover trials, analyze results, and generate evidence.

PURE Evidence

Transforms fragmented clinical research into structured, reliable, and continuously updated evidence to support development decisions.

Design Studio

Enables clinical trial design, statistical calculations, and simulation of alternative development strategies.

SynthIPD

Reconstructs synthetic individual patient data from published clinical evidence to support advanced statistical analyses.

Stat Programming

Supports the generation of SDTM, ADaM, and tables, listings, and figures through AI-enabled statistical programming workflows.

Regulatory Navigator

Helps development teams navigate regulatory requirements, guidelines, and precedents.

We envision additional specialized agents supporting clinical operations, patient recruitment, medical strategy, and commercialization.

These applications are not intended to operate as disconnected products. They are built on a shared platform, allowing improvements in data infrastructure, agent capabilities, workflow orchestration, and validation to benefit the broader HopeAI ecosystem.

Over time, we expect customers to increasingly use multiple agents together, enabling workflows that extend across traditional functional boundaries.

04 / Our operating model

AI Partners — Bringing Specialized Intelligence Into Customer Workflows

Technology alone does not transform how organizations operate.

Drug development requires scientific judgment, domain expertise, organizational alignment, and confidence in the reliability of analytical outputs.

HopeAI’s AI Partners work directly with customers to translate complex development challenges into AI-native solutions. They combine deep expertise in drug development with the ability to configure, deploy, and continuously improve specialized AI agents.

They collaborate with customers to understand their objectives, design solutions, validate outputs, and integrate AI capabilities into real-world workflows.

Unlike traditional consulting engagements, our AI Partner model is designed to generate reusable intelligence. Solutions developed for individual customers inform the development of specialized agents, validated workflows, and platform capabilities that can subsequently benefit a broader customer base, subject to confidentiality and data rights.

Our AI Engineers complement this work by developing the underlying platform, infrastructure, agent frameworks, and shared technical capabilities required to scale.

We believe this combination of domain expertise, customer proximity, and scalable engineering is central to HopeAI’s long-term differentiation.

05 / Customer relationships

A Platform Customers Build Their Drug Development Operations On

As customers adopt HopeAI Workspace, we seek to become increasingly integrated into their development processes.

A relationship may begin with a single application, such as clinical evidence generation or statistical analysis. Over time, customers can expand into additional workflows, connecting clinical evidence, study design, statistical programming, regulatory strategy, and operational execution within the same environment.

As organizations incorporate their internal knowledge, proprietary data, validated methods, and development processes into HopeAI Workspace, the platform can become increasingly valuable to their operations.

We believe this integration can create durable customer relationships and meaningful switching costs.

Our long-term vision is for HopeAI Workspace to evolve from a collection of specialized AI applications into an essential intelligence and execution layer for drug development.

Rather than replacing the expertise of scientists and development professionals, we aim to multiply their capabilities and enable them to accomplish work that would otherwise require substantially greater time and resources.

06 / Access

Democratizing Access to Drug Development Intelligence

We believe the transformative potential of AI in drug development should not be limited to organizations with the largest budgets or technical resources.

Our vision is to make specialized drug development intelligence accessible to researchers, clinicians, biotechnology companies, and pharmaceutical enterprises around the world.

Through TrialScape, we aim to democratize access to clinical trial intelligence, enabling anyone to discover clinical trials, explore scientific evidence, and better understand the evolving landscape of medical research.

Through HopeAI Workspace, we provide increasingly sophisticated AI capabilities that support critical decisions and workflows throughout drug development.

Our AI Partners work alongside customers to bring these capabilities into real-world development environments, combining specialized intelligence with deep scientific and operational expertise.

We believe that making AI accessible, useful, and trustworthy can accelerate adoption across the life sciences ecosystem.

As more organizations embrace AI-native approaches, we envision a future in which advanced drug development capabilities become available to companies of all sizes, enabling more promising medicines to reach patients.

07 / Product philosophy

Building With Customers, Building for Scale

Build with customers, but build for scale.

Drug development challenges are highly specialized, and many of the most valuable applications of AI cannot be fully anticipated without working alongside domain experts.

We therefore view customer engagements as an important source of product innovation. However, we do not intend to operate primarily as a traditional services organization.

Our objective is to systematically convert customer-specific solutions into reusable platform capabilities.

Each successful engagement can contribute new agent skills, validated workflows, data assets, or technical components to HopeAI Workspace.

As our library of specialized intelligence expands, we expect to address additional use cases with greater speed and efficiency.

We believe this model can allow HopeAI to combine the depth of a specialized AI services organization with the scalability of a software platform.

08 / Partnerships

Becoming the AI-Native Development Partner for Biotechnology Companies

Beyond serving established pharmaceutical enterprises, we see a significant opportunity to partner with emerging biotechnology companies from their earliest stages.

Many biotechnology companies possess promising scientific assets but face substantial financial and operational constraints in advancing them through clinical development.

We believe AI-native development models can enable these companies to operate with greater efficiency and access capabilities traditionally available only to larger organizations.

HopeAI aims to partner with biotechnology founders, investors, and development teams to embed AI into their operating models from inception.

Through HopeAI Workspace and our AI Partners, we seek to provide an integrated development capability spanning evidence generation, clinical strategy, study design, statistical analysis, regulatory planning, and clinical operations.

We partner with biotechnology founders and investors to build AI-native drug development companies, aligning our capabilities and incentives with their long-term success.

Over time, we envision a network of AI-native biotechnology companies leveraging a common intelligence platform while pursuing distinct therapeutic opportunities.

09 / Long-term vision

Our Long-Term Opportunity — Enabling AI-Native Drug Development at Scale

We believe the economic opportunity created by AI in drug development extends far beyond productivity improvements in existing workflows.

Today, drug development remains constrained by the cost, time, and organizational complexity required to advance promising medicines.

As specialized AI capabilities improve, we expect increasingly sophisticated development activities to become more accessible, scalable, and efficient.

Our long-term ambition is to help create an environment in which a promising therapeutic discovery—whether originating from an academic laboratory, a biotechnology startup, or an AI-driven discovery company—can be advanced through clinical development using an integrated AI-native operating model.

In this future, HopeAI would provide the specialized intelligence, validated workflows, and development expertise required to help transform scientific discoveries into medicines.

We believe this opportunity represents a fundamental expansion of our addressable market.

Our objective is not merely to sell software to the existing drug development industry. Our objective is to help redefine how the industry develops medicines.

By combining specialized intelligence, an integrated AI-native workspace, and deeply embedded AI Partners, we aspire to become a foundational platform for the next generation of drug development.